Table 1 Baseline characteristics of 46 patients* in the phase II part
From: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
Characteristic | Number of patients (%) |
|---|---|
Sex | |
Male | 31 (67) |
Female | 15 (33) |
ECOG performance status | |
0 | 29 (63) |
1 | 17 (37) |
Histology | |
Intestinal | 29 (63) |
Diffuse | 17 (37) |
Metastatic sites | |
Lymph nodes | 35 (76) |
Liver | 22 (48) |
Ovary | 1 (2) |
Spleen | 1 (2) |
Rectum | 1 (2) |
Adrenal gland | 1 (2) |
Gastric remnant | 1 (2) |
No of metastatic sites | |
1 | 31 (67) |
2 | 14 (30) |
3 | 1 (2) |
Prior therapy | |
None | 25 (54) |
Any prior therapy | 21 (46) |
Surgery | 13 (28) |
Chemotherapy | 16 (35) |
